Highlights AlloVir, Inc.

Equities

ALVR

US0198181036

Real-time Estimate Cboe BZX Other stock markets 01:44:05 2024-04-29 pm EDT			5-day change	1st Jan Change
0.807 ^USD	+1.24%		+4.77%	+17.59%

Mar. 20	North American Morning Briefing : Markets on Hold -2-	DJ
Mar. 15	AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Highlights

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 15	CI
North American Morning Briefing : Stock Futures -2-	Mar. 13	DJ
AlloVir scraps late-stage studies testing lead cell therapy	Dec. 22	RE
AlloVir scraps late-stage studies testing antiviral cell therapy	Dec. 22	RE
AlloVir, Inc. Provides Updates on Phase 3 Clinical Development Program for Posoleucel, an Allogeneic Virus-Specific T Cell Therapy	Dec. 22	CI
AlloVir, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 02	CI
AlloVir, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
AlloVir Shares Jump in Premarket Thursday After Gilead Sciences Acquires 2.93 Million Shares	23-06-29	MT
AlloVir, Inc. Presents Positive Final Results from A Phase 2 Randomized, Placebo-Controlled Trial Evaluating Posoleucel Treatment of Bk Infection in Kidney Transplant Recipients At the American Transplant Congress	23-06-05	CI
ALLOVIR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	23-05-04	AQ
AlloVir, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-04	CI
ALLOVIR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-K)	23-02-15	AQ
AlloVir Loss Narrows in 2022; Issues 2023 Outlook	23-02-15	MT
AlloVir, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-15	CI
AlloVir Announces Positive Final Results from Randomized, Double-Blind, Placebo-Controlled Phase 2 Study of Posoleucel in Kidney Transplant Recipients with BK Viremia	23-02-15	CI
AlloVir, Inc. Announces Plans to Complete Enrollment in Three Phase 3 Posoleucel Studies in 2023	23-01-09	CI
AlloVir, Inc. Announces Positive Final Results in Phase 2 Posoleucel Multi-Virus Prevention Study	22-12-10	CI
ALLOVIR, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations. (form 10-Q)	22-11-03	AQ
AlloVir, Inc. Announces That Final Data from the Phase 2 Study of Posoleuce	22-11-03	CI
AlloVir, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-03	CI

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Highlights AlloVir, Inc.

Equities

ALVR

US0198181036

Highlights

Filters